

# Alfonso GÃ³mez de LiaÃ±o Lista

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3278850/publications.pdf>

Version: 2024-02-01

7  
papers

1,425  
citations

2258001

3  
h-index

2550070

3  
g-index

7  
all docs

7  
docs citations

7  
times ranked

2704  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al.'s Letter to the Editor re: Alfonso GÃ³mez de LiaÃ±o Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. <i>European Urology</i> , 2021, 79, e20-e21.	1.9	0
2	Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. <i>European Urology</i> , 2020, 77, 269-276.	1.9	45
3	Patient Perspective on the Management of Cancer Pain in Spain. <i>Journal of Patient Experience</i> , 2020, 7, 1417-1424.	0.9	4
4	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
5	Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 514-514.	1.6	0
6	High responses to chemotherapy in patients with metastatic urothelial cancer (MUC) after frontline immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 377-377.	1.6	0
7	Molecular subtyping of metastatic urothelial bladder cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 326-326.	1.6	0